Tag:

RNAi

Latest Headlines

Latest Headlines

Market research firm: RNA-based drugs to exceed $1B in sales by 2020

Market research firm Allied Market Research forecasts that RNA-based therapies will generate $1.2 billion in revenue by 2020, a compounded annual growth rate of 28.4%, according to a recent report.

RNAi pipeline active as investors, patients wait for commercialization

A while ago, there was talk of a dreaded biotech bubble, and Novartis' decision to slam the breaks on its RNA interference research was making waves. But lately, the talk has turned positive on the promising yet unproven treatment paradigm, which utilizes RNAi to deliver gene-based therapy.

Arrowhead updates TheStreet on clinical trial results of RNAi candidate for hepatitis B

Arrowhead Research reported on Aug. 12 that patients in its Phase II clinical trial of the ARC-520 RNA interference candidate for hepatitis B had a "similar" knockdown to those reported in primate studies. The stock price fell at the very end of the trading day to close at $12.00 from an opening-day price of $13.00.

Patent Office grants Alnylam new claims on its RNAi delivery method

Alnylam announced July 22 that its intellectual property estate has been strengthened due to the U.S. Patent Office's issuance of a Notice of Allowance for claims in one of its patent applications that covers "chemically modified RNA therapeutics conjugated with an N-acetylgalactosamine (GalNAc) ligand independent of length, sequence, or disease target," according to a statement. 

UPDATED: Alnylam's hepatitis B therapy shows promise in animal studies

RNAi specialist Alnylam is adding a hepatitis B virus therapy to its pipeline of candidates that employ its Enhanced Stabilization Chemistry-GalNAc-conjugate technology enabling subcutaneous dosing and plans to file an IND by the end of 2015.

MIT researchers deliver low doses of siRNA to lung endothelial cells

One of the chief drawbacks of RNA interference therapies so far has been the difficulty of delivering small interfering RNA to cells outside the liver. That's why a newly reported breakthrough in delivering siRNA to endothelial cells in the lung and other organs is a big deal.

Alnylam COO on Novartis RNAi pullout: Big Pharma has 'never been able to innovate'

The COO of RNAi specialist Alnylam was critical of Big Pharma in the wake of Novartis' decision to slam the breaks on its RNAi research. The news made investors nervous about the future of the promising, but nascent technology and Alnylam stock price is down more than 20% in the last week.

Novartis slams the brakes on once-ambitious RNAi development efforts

Novartis is shuttering a large part of its once-ambitious RNAi research effort in Boston, FierceBiotech has learned. The pharma giant, which has extensive research operations in the Boston area, confirmed the decision, saying that the lingering problems associated with delivering these therapies tied to the small number of relevant targets they could shoot for drove the move.

The year in nanotech drug delivery

Here at FierceDrugDelivery, we write often about innovations in nanotechnology as it becomes more and more important in the delivery field. These advances are mostly in the very early stages, but they're still promising as the delivery field moves even further into the nanoscale.

Arrowhead doses first RNAi hepatitis B 'functional cure' PhIIa patient

Arrowhead, fresh off a $120 million public offering in February, is paving the way on what it has called a "functional cure" for hepatitis B, beginning dosing in a Phase IIa trial for its RNAi drug designed to deliver the genetic material to the nucleus using a polymer-based conjugate.